AFF1 and acute lymphoblastic leukemia: Blinatumomab has shown promising therapeutic results in refractory or relapsed B-ALL; however, it has potential risk of inducing lineage switch, especially in <i>KMT2A/AFF1</i> rearranged B-ALL into acute myeloid leukemia and/or myeloid sarcoma.